Clinical Utility of an Alzheimer's Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey Study.

MLA

Monane, Mark, et al. “Clinical Utility of an Alzheimer’s Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey Study.” Diagnostics (2075-4418), vol. 15, no. 2, Jan. 2025, p. 167. EBSCOhost, https://doi.org/10.3390/diagnostics15020167.

APA

Monane, M., Maraganore, D. M., Carlile, R. M., Johnson, K. G., Merrill, D. A., Gitelman, D. R., Sharlin, K. S., VandeVrede, L. A., George, K. K., Wang, J., West, T., Jacobs, L., Verghese, P. B., & Braunstein, J. B. (2025). Clinical Utility of an Alzheimer’s Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey Study. Diagnostics (2075-4418), 15(2), 167. https://doi.org/10.3390/diagnostics15020167

Chicago

Monane, Mark, Demetrius M. Maraganore, Robert M. Carlile, Kim G. Johnson, David A. Merrill, Darren R. Gitelman, Kenneth S. Sharlin, et al. 2025. “Clinical Utility of an Alzheimer’s Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey Study.” Diagnostics (2075-4418) 15 (2): 167. doi:10.3390/diagnostics15020167.